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Chapter 3
US multicenter trials of endoprostheses for the
endovascular treatment of descending thoracic
aneurysms
Jae-Sung Cho, MD, Shan-e-ali Haider, MD, and Michel S. Makaroun, MD, Pittsburgh, PaSince the first report of endovascular therapy for de-
scending thoracic aortic pathology in 1994 by Dake et al,1
the advent of commercially available devices has been rela-
tively slow. This is primarily due to the relatively lower
volume of thoracic aortic aneurysms as compared with
infrarenal aortic aneurysms. Technical and anatomic chal-
lenges in thoracic endografting, such as proximity of the
great vessels and tortuosity around the arch, also pose a
challenge. In addition, a larger device profile and hostile
hemodynamic forces complicate the technical aspect of the
deployment procedure.
With broadened applications for endovascular treat-
ment of thoracic pathology worldwide,2-4 including aortic
dissections, aneurysmal degeneration of chronic dissec-
tions, traumatic ruptures, and penetrating ulcers, there
has been an increased focus on the development of
thoracic endoprostheses. As many as 12 thoracic en-
dografts are currently available for commercial use in
Europe.
In the United States, only one thoracic endoprosthesis,
the Gore Thoracic Aortic Graft (TAG) device (W.L. Gore
and Associates, Flagstaff, Ariz), has gained US Food and
Drug Administration (FDA) approval for treatment of de-
scending thoracic aortic aneurysms (DTAs) and is commer-
cially available. Two other devices are undergoing US
multicenter trials: the TX2 device (Cook, Bloomington,
Ind) and the Talent stent graft (Medtronic AVE, Sunrise,
Fla). This chapter provides an update on these three devices
and the available data on the US trials.
GORE TAG THORACIC ENDOPROSTHESIS
The Gore Excluder thoracic endoprosthesis was the
first thoracic endograft to enter clinical trials in the United
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12AStates in 1998 with a feasibility trial. This was followed by
the pivotal study in 1999. After the conclusion of the trial,
the discovery of longitudinal deployment wire fractures led
to the withdrawal of the device from distribution in May
2001. The device wasmodified with the removal of the wire
and replacement by a stronger polytetrafluoroethylene
(PTFE) with a new bonding of the sinusoidal wire. A
confirmatory trial was instituted in late 2003 with the
modified device. In March 2005, the FDA approved com-
mercial use of the TAG device.
DEVICE DESIGN
The TAG endoprosthesis is a symmetrical expanded
PTFE (ePTFE) tube reinforced with ePTFE/fluorinated
ethylene propylene (FEP) film and an external nickel-
titanium (nitinol) self-expanding stent along the entire
surface of the graft (Fig 1). The stent is attached to the graft
with ePTFE/FEP bonding tape. A circumferential PTFE
sealing cuff is located on the external surface of the en-
dograft at the base of each flared, scalloped end. Flares are
designed to help with conforming to tortuous anatomy.
Each cuff is circumferentially attached on one edge with
FEP, thus allowing the other end to remain free to enhance
sealing of the endoprosthesis to the aortic wall and help
eliminate endoleaks.
The original TAG device graft material was constructed
from 2 ePTFE layers with 2 longitudinal wires for support
during deployment. The modified TAG device is con-
structed from 3 ePTFE layers. The additional layer, similar
to that incorporated into the Excluder bifurcated endo-
prosthesis, is sandwiched between the two original layers
and provides support that was formerly provided by the
deployment wires. At the base of the flares are two ra-
diopaque gold bands, which serve as a guide during implan-
tation and in follow-up. The devices are available in 26- to
40-mm diameters and require 20F through 24F introducer
sheaths, depending on the device size.
Deployment of the TAG device is unique. A sleeve
made of ePTFE/FEP film is used to constrain the en-
dograft. A deployment knob is located at the control end of
the delivery catheter and has a deployment line that runs
the entire length of the catheter connecting it to the sleeve.
Turning and pulling the deployment knob removes the
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The device is deployed rapidly from the middle of the
endograft toward both ends of the prosthesis. The device is
then secured in position with a specially designed tri-
lobed balloon, which allows continuous blood flow dur-
ing inflation.
FEASIBILITY STUDY
The first trial to be conducted in the United States was
the feasibility study to establish preliminary device safety
data. This study was performed at two sites in the United
States and enrolled a total of 28 patients between 1998 and
1999. The 30-day mortality rate was 3.6% (n  1). At 1
year, the mortality rate was 21% without any paraplegia or
stroke. Renal failure and myocardial infarction were noted
in one patient each (3.6%). Through a 5-year follow-up
period, two additional adverse events were reported be-
tween 2 and 5 years. All-cause mortality at 5 years was 25%.
Endoleaks were noted at any time in 21% of the patients,
and aneurysm sac growth was noted in 18%. Stent fractures
were noted in 32%. There was one conversion and there
were two reinterventions over time to place additional
devices. No aneurysm ruptures, device migration, extru-
sion, erosion, lumen obstruction, or branch vessel occlu-
sions were reported.
PIVOTAL (PHASE II) TRIAL
Objectives and hypotheses
The objectives were to determine the safety and
efficacy of the TAG endoprosthesis for the treatment of
DTA as compared with open surgical repair controls.
The primary safety hypothesis was that the percentage of
subjects with one or more major adverse events (MAEs)
through 1 year after treatment would be lower in the
TAG group as compared with the surgical control group.
The primary efficacy hypothesis was that freedom from
any major device-related events through 1 year of fol-
low-up for the TAG device group would be better than
Fig 1. Gore TAG thoracic endoprosthesis.80%. A predefined point estimate of 80% for the endo-vascular group was considered to be a reasonable efficacy
outcome, because the device was expected to show a
considerable improvement in safety profile. The efficacy
for the surgical procedure was assumed to be 100%. The
secondary hypotheses were that the procedural blood
loss, intensive care unit (ICU) and hospital stay, and
convalescence to normal activities would be lower in the
TAG device group as compared with the surgical control
group. The primary efficacy end point of this pivotal
study was the percentage of subjects who were free from
major device-related events through 1 year of follow-up
for the TAG device group.
Study design
This study was a prospective, nonrandomized, con-
trolled multicenter trial. The study enrolled 140 study
patients and 94 control subjects between September 1999
and May 2001 through 17 clinical sites in the United
States. The control group consisted of 44 patients acquired
prospectively during the study and 50 historical patients
acquired by selecting the most recent surgical patients in
reverse chronological order. Inclusion and exclusion crite-
ria are detailed in Tables I and II.
Follow-up
All patients are to be followed for 5 years. Computed
tomography (CT) scans, plain radiographs, and physical
examinations were obtained at 1-month, 6-month, and 12-
month intervals and yearly thereafter. A 3-month visit with
a CT scan was conducted for patients with early endoleaks.
A core laboratory reviewed all imaging studies. Clinical data
were reported by individual centers and monitored by
sponsor representatives. MAEs were adjudicated by the
Clinical Events Committee and defined as clinical events
that required therapy or that resulted in an unintended
increase in the level of care, prolonged hospitalization,
permanent adversity, or death.5 Minor adverse events were
those that did not require any therapy or those with no
consequences.
RESULTS OF THE PIVOTAL STUDY
Clinical material
The TAG group and the surgical group were very
similar in all major demographic and clinical variables
(Table III). The average age of the patients was 71 years in
the TAG group and 68 years in the control group. Men
accounted for 58% of the patients in the TAG group and
51% in the control group.
Baseline aortic morphology was also well matched
between the groups, except for the smaller diameter of
the proximal and distal necks in the TAG device group,
which was expected because of the requirements for
sealing. Baseline comorbidities were also quite similar
between the TAG device group and the control group
(Table IV). Although coronary artery disease seemed to
be more prevalent among the TAG group, this difference
was not significant. Symptomatic aneurysms, however,
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than in the TAG group. The risk classifications per-
formed on the basis of the standard American Society of
Anesthesiologists classification and the SVS risk score
Table I. Inclusion criteria
Criterion Medtronic Talent
Age (y) 18
Women Negative pregnancy test 7 d
before treatment
Open-surgical candidate Yes
Neck length Minimal 2 cm proximal and
distal
Aneurysm Fusiform DTA at least twice
the size of normal
thoracic aorta; saccular
Penetrating ulcer Yes
Proximal landing zone location 20 mm distal to left CCA
Distal landing zone location 20 mm proximal to celiac
axis
Landing zone diameter (mm) 18-42
CCA, Common carotid artery; DTA, descending thoracic aortic aneurysm.
Table II. Exclusion criteria
Criterion
Medtronic
Talent
Cook
TX2
Gore
TAG
Creatinine (mg/dL) 2.0
Unstable rupture N/A Yes Yes
Mycotic aneurysm Yes Yes Yes
Connective tissue disease Yes Yes Yes
Significant landing zone
thrombus Yes Yes Yes
Previous descending aortic
surgery or endovascular
repair of DTA or AAA Yes Yes N/A
Aortic dissection Yes Yes Yes
Coagulopathy Yes Yes Yes
MI/CVA 3 mo 3 mo 6 wk
Major operation within 30 d Yes Yes Yes
Participation in another
investigational study 30 d 30 d 1 y
DTA, Descending thoracic aortic aneurysm; AAA, abdominal aortic aneu-
rysm; MI, myocardial infarction; CVA, cerebrovascular accident; N/A, not
applicable.
Table III. Patient demographics
Variable TAG group Surgical control
Male (%) 57 51
Age (y) 71 68
Ethnicity (%)
White 87 86
Black 8 10
Other 5 4
Height (cm) 170 170
Weight (kg) 76 78showed no significant difference in either classification.Operative data
Of 142 patients recruited (140 in the pivotal trial and
2 extended access), 139 (98%) underwent successful
implantation of the TAG device. The three failures were
all due to poor iliac access. A conduit was placed to
facilitate access in 21 patients (15%). More than 1 device
was used in 77 patients (55%); 61 patients (44%) received
2 devices, 11 patients (8%) received 3 devices, and 5
patients (4%) received 4 devices.
Prophylactic left carotid/subclavian bypass grafting
was performed in 28 patients in preparation for planned left
subclavian artery coverage with the device. Unplanned
subclavian artery and visceral artery coverage occurred in
one patient each. The latter underwent an open abdominal
explantation of the device and redeployment of a new
Cook TX2 Gore TAG
18 21
Negative pregnancy test 7 d
before treatment
Must be infertile
Yes Yes
Minimal 3 cm proximal and
distal
Minimal 2 cm proximal and
distal
Fusiform DTA at least twice
the size of normal
thoracic aorta
Fusiform DTA at least
twice the size of normal
thoracic aorta; saccular
No No
30 mm distal to left CCA 20 mm distal to left CCA
20 mm proximal to celiac
axis
20 mm proximal to celiac
axis
24-38 23-37
Table IV. Comparison of early complications between
TAG and open surgical controls in the GORE pivotal
trial
Variable
TAG
device (%)
Surgical
control (%) P value
Coronary artery disease 49 36 .06
Cardiac arrhythmia 24 31 .23
Stroke 10 10 .95
PVOD 16 11 .33
Prior vascular intervention 45 55 .14
Symptomatic aneurysm 21 38 .01
Other concomitant aneurysms 28 28 .95
COPD 40 38 .89
Smoking 84 82 .86
Renal dialysis 1 0 .52
Hepatic dysfunction 2 1 .65
Paraplegia 1 0 .95
Cancer 19 13 .21
PVOD, Peripheral vascular occlusive disease; COPD, chronic obstructive
pulmonary disease.device without sequelae.
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Mortality. Operative mortality, defined as death within
30 days of the procedure or on the same hospital admission,
occurred in three patients (2.1%) after TAG implantation
(Table V). One death was due to a postoperative stroke and
another to a cardiac event that occurred on postoperative
day 11. The third death occurred after 7 months of a
protracted hospital course as a result of anoxic brain injury
after a respiratory arrest. The patient died of septic compli-
cations from an aortoesophageal fistula. Six deaths (6.4%)
occurred in the surgical control group.
Spinal cord ischemia. Spinal drainage was not rou-
tinely used in either group. In the TAG group, spinal cord
ischemia (SCI) was noted in four patients. One was noted
immediately after the procedure, and the deficit persisted
despite all supportive measures. Three were delayed in onset,
and all these regained motor function (one complete and two
partial) and were ambulatory at last follow-up. It should be
noted that multiple pieces of TAG endografts were used in
three of four patients and that two of four patients had had
previous infrarenal aortic aneurysm repair. The incidence of
SCI did not differ between those with and without prior
abdominal aortic aneurysm repair (4.7% vs 2%, respec-
tively). The incidence of SCI in the control group was
significantly higher (13.8%). Of 13 patients, 8 had paraple-
gia, of whom 6 died. One case of paraplegia resolved
completely.
Cerebrovascular accidents. Perioperative stroke was
noted in five patients (3.5%). One was fatal. Three were
right-sided. Four of the five strokes occurred in patients
who had proximal aneurysms requiring extension of the
TAG to the left carotid and coverage of the subclavian
artery; all four underwent carotid/subclavian bypass. Of
the 28 patients with proximal aneurysms who had planned
subclavian artery coverage, 4 (14%) had a stroke, compared
with 1 (1%) of 114 with disease distal to the subclavian
artery (P .001). The overall incidence of cerebrovascular
accident (4.3%) was similar in the two groups.
Endoleaks. Early endoleaks were seen in five patients.
One patient had a proximal type I endoleak and was treated
with endovascular revision and additional grafts. The re-
maining endoleaks were thought to be type II.
Other MAEs. The other most common MAEs were
bleeding, cardiopulmonary events, and intraoperative vas-
cular injury. Both bleeding and pulmonary events were
significantly reduced in the TAG group compared with the
surgical control group, due to a high percentage of proce-
dural bleeding and respiratory failure in the latter.
The incidence of vascular injuries was 14% in the TAG
Table V. Operative complications
Variable TAG Open surgical
Death 2.1 11.7
Paraplegia/paraparesis 3 14
Stroke 4 4group, which was significantly higher than in the controlgroup (4%). This was related to the introduction of large
introducer sheaths through the iliac system.
Hospital length of stay. The average ICU stay was
significantly shorter in the TAG group compared with the
control group (2.6  14.6 days vs 5.2  7.2 days; P 
.001), as was total length of stay (7.4 17.7 days vs 14.4
12.8 days; P  .001).
Late outcome
Late survival. All-cause mortality through 3 years did
not differ in the two groups (Fig 2). The causes of death
were commensurate with associated comorbidities in this
elderly population. No ruptures have been reported.
With respect to aneurysm-related mortality, defined as
death before hospital discharge, death within 30 days of the
primary procedure or within 30 days of any secondary
procedure to treat the original aneurysm, or death due to
aneurysm rupture, there was one late death in the TAG
group. This patient had an aneurysm growth in the setting
of graft infection at 2 months. The patient underwent an
open conversion and was found to have an aortoesophageal
fistula, which was treated by graft excision and an extra-
anatomic bypass, only to experience a respiratory arrest on
postoperative day 13with resultant anoxic brain injury. The
patient died 3 days later. In the open-surgical group, three
additional deaths occurred during the first 6 months of
follow-up. Freedom from aneurysm-related mortality
through 3 years was 97% for the TAGdevice group and 90%
for the open-surgical controls (P  .024). No mortalities
were noted in either group after the first year (Fig 3).
Major adverse events. The Kaplan-Meier estimates of
the probability of freedom from MAEs were significantly
higher with TAG treatment (58%) than with open surgical
controls: 48% vs 20% at 3 years, respectively (Fig 4). In fact,
70% of all MAEs occurred within 30 days of the original
procedure. A similar observation was made in the feasibility
study, in which 63% of all events over 5 years were noticed
Fig 2. Comparison of Kaplan-Meier estimates for all-cause mor-
tality through the 3-year follow-up between the Gore TAG and
surgical control groups.in the first 30 days.
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five patients underwent endovascular revisions, and one
patient underwent surgical conversion. Three of the
revisions occurred after 24 months of follow-up. Device
migrations, three proximal and four component, were
noted without clinical compromise at the 2-year follow-
up. Sac shrinkage of greater than 5 mm was observed in
38% (24/64) and sac expansion in 17% (11/64) of
patients. Three of the 11 patients with sac enlargement
had endoleaks at some point during follow-up. Twenty
fractures were noted in 19 patients: 18 in the longitudi-
nal spine and 2 in the apical nitinol support rings.
Clinical sequelae developed in only one patient, who
developed a type III endoleak that was treated with an
endograft. No ruptures were noted at a follow-up ex-
tending to 2 years. No device-related deaths were noted
Fig 3. Comparison of Kaplan-Meier estimates for aneurysm-re-
lated mortality through 3-year follow-up between the Gore TAG
and surgical control groups.
Fig 4. Comparison of Kaplan-Meier estimates for freedom from
major adverse events through the 3-year follow-up between the
Gore TAG and surgical control groups.through 3 years.CONFIRMATORY STUDY
Objectives and hypotheses
The confirmatory study was launched to demonstrate
that deployment and early results with the modified device
are comparable to those with the original device. The safety
and efficacy hypotheses were the same as in the pivotal trial
except for using a 30-day end point. This earlier safety end
point was chosen as an appropriate measure on the basis of
the results of the pivotal study, in which most MAEs
occurred within the 30-day period. Almost all major
device-related events were also identified in the first 30 days
during the pivotal trial. Although 30-day study end points
were used, all patients are to be followed up to 5 years.
Inclusion and exclusion criteria were identical to those used
in the pivotal study.
Design
The confirmatory study was a prospective, nonrandom-
ized trial with all test subjects treated with the modified
TAG device. The study was performed at 11 sites, all but
one of which had participated in the pivotal trial. Fifty-one
patients were enrolled in this study, and their results were
compared with the same 94 control subjects used in the
pivotal study.
Results of the confirmatory study
Clinical materials. Baseline demographics and aortic
morphology were quite similar in the TAG device group
and the surgical control group. Comorbidities were also
well matched. In this comparison, the symptomatic aneu-
rysm difference did not reach statistical significance. How-
ever, there was a higher prevalence of cancer or a history of
cancer in the TAG device group compared with the surgical
control group. Risk classification according to the Ameri-
can Society of Anesthesiologists was very well matched
between the TAG and the surgical control groups. The SVS
risk score was slightly higher in the TAG device group, and
this was significant.
Early MAEs. At 30 days, the incidence of MAEs was
12% in the TAG group and 70% in the controls, a highly
significant difference corresponding to an 83% risk reduc-
tion for those treated with the TAG device. No early deaths
were noted in the TAG group. The rate of vascular compli-
cations was not significantly different in this cohort com-
pared with the surgical controls.
Kaplan-Meier estimates of the probability of freedom
from MAEs through 30 days showed a significant advan-
tage for the TAG device group compared with the surgical
control group (P  .001).
Device-related events. No major device-related events
were reported through the 30-day follow-up in the test
subjects compared with six (4%) reported for the pivotal
study test subjects.
Hospital length of stay. Hospital length of stay was
shorter with the TAG device compared with the control
group (3 vs 10 days, respectively). The time to return to
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days vs 78 days for the control group.
MEDTRONIC TALENT THORACIC
ENDOGRAFT AND THE VALOR TRIAL
Device design
The Talent Thoracic Stent Graft device is composed of
a polyester graft fabric sewn to a self-expanding nitinol wire
frame (Fig 5). It is a modular device that accommodates the
use of additional main sections, as well as proximal and
distal extensions. The proximal end of the device is usually
a bare stent for better proximal fixation. The graft diame-
ters are 18 through 42mm, and the delivery catheter profile
ranges from 22F to 25F. The stent grafts are selected on the
basis of anatomic measurements. Deployment systemmod-
ifications were introduced later in the trial, and a modified
device, the Valiant system (Medtronic, Inc, Minneapolis,
Minnesota), has been introduced in Europe recently.
The VALOR trial
The VALOR trial (Vascular Talent Thoracic Stent
Graft System for the Treatment of Thoracic Aortic Aneu-
rysms) is a prospective, multicenter study with 3 arms
conducted at 35 sites in the United States. Enrollment for
the study concluded in June 2005 with 394 patients total,
and final VALOR trial results may be available by 2006.
The test group (n  144) consisted of patients who were
diagnosed with DTA and were considered candidates for
open surgical repair with low- to moderate-risk Society for
Vascular Surgery/International Society for Cardiovascular
Surgery criteria. The test group inclusion/exclusion criteria
are listed in Tables I and II. No surgical control arm was
included, and the comparative open control arm would be
derived from the established literature. In addition to the
test group, two additional observational treatment group
registries were conducted concurrently. The registry group
(n 150) enrolled subjects who were open-surgical candi-
dates with complicated type B thoracic aortic dissections,
aneurysmal degeneration from dissection, pseudoaneu-
rysms, and chronic, stable traumatic injuries. The last arm
Fig 5. Medtronic Talent stent graft.was a high-risk group (n 100). Patient eligibility includedpatients considered at high risk for open surgery, nonsur-
gical candidates not associated with Society for Vascular
Surgery scoring, and subjects with traumatic thoracic aortic
injuries. Only the data from the test arm will be used in
device safety and efficacy analysis. The information from
the registries will be descriptive in nature and may serve as
the basis for future phase III clinical investigations.
The primary objective of the study is to determine the
safety and efficacy of the Talent device in the treatment of
DTA in subjects who are otherwise eligible for standard
open repair. The safety end point compares the all-cause
mortality of DTA repair with the Talent endograft against
the literature control for open surgical repair within 1 year
of follow-up. The efficacy end point measures the propor-
tion of subjects with successful aneurysm treatment at the
12-month follow-up.
The secondary safety and efficacy end points evaluate
the technical success rate, the percentage of subjects with
MAEs, device-related events, and aneurysm rupture rates at
30 days and at 12 months. Additional data analysis will
include blood loss, blood product transfusion, operative
time, ICU stay, and overall length of hospital stay. The
VALOR trial reached its enrollment target in June 2005,
and no results are yet available.
Subject screening required a minimum of a contrast-
enhanced spiral CT scan of the chest, abdomen, and
pelvis with optional three-dimensional reconstruction or
contrast-enhanced magnetic resonance arteriography. His-
tory and physical, chest radiograph, and CT or magnetic
resonance arteriography of the chest were obtained at 1, 6,
and 12 months and yearly thereafter.
COOK ZENITH TX2 THORACIC ENDOGRAFT
AND THE STARZ TRIAL
Device description
The Zenith endograft is a one-piece (TX1) or two-
piece (TX2) modular endovascular graft (Fig 6). The TX2
is the endograft used in the US trials. The device composi-
tion is of Dacron (DuPont, Wilmington, Del) fabric sewn
to self-expanding stainless steel Z-stents with braided poly-
ester and monofilament polypropylene sutures. The graft is
fully stented with an intention to provide columnar stability
and expansile force. It consists of a proximal (TX2P) and a
distal (TX2D) component, with a minimal overlap of 2
stents between them. The proximal part of the TX2P is
covered and contains a series of 5-mm-long, staggered,
caudally oriented barbs to prevent distal migration. Proxi-
mally, the distal TX2 component has a two-stent overlap
zone in which the stents are sutured to the internal surface
of the fabric. Distally, there is an uncovered Gianturco
Z-stent with cranially oriented barbs to help prevent prox-
imal migration. Four gold radiopaque markers are sta-
tioned near the edge of the graft material to enhance
visualization of graft ends. The graft diameters range from
28 to 42 mm, and the graft profile ranges from 20F to 22F.
The proximal components can either be tapered or nonta-
pered. The device is deployed by manually retracting the
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graft in position.
Additional ancillary endovascular components (proxi-
mal and distal main body extensions) are available. The
TX2 ancillary components are cylindrical components con-
structed from the same polyester fabric and materials. At
the distal and proximal graft margins, the Z-stents are
attached to the inner surface. Elsewhere, the Z-stents are
sutured on the external surface.
The STARZ trial
The STARZ-TX2 trial (Study of Thoracic Aortic An-
eurysm Repair with the Zenith TX2 TAA Endovascular
Graft) is a North American multicenter, nonrandomized,
prospective clinical trial. It is seeking to enroll 270 patients
at 35 sites in the United States and Canada. It includes a
control group consisting of patients with concurrent and
recent historical open surgical procedures. Subject selec-
tion will be based on the inclusion and exclusion criteria
listed in Tables I and II. Control subjects are those who do
not meet the anatomic inclusion criteria for the endovascu-
lar treatment group but otherwise fit the study criteria.
The primary safety hypothesis is that the subjects treated
with the Zenith device will have 30-day survival rates equiva-
Fig 6. Cook Zenith TX2 thoracic endovascular graft.lent to those of the surgical control group. The secondaryhypothesis under investigation is that patients treatedwith the
TX2 stent graft will have equivalent or fewer complications
compared with the surgical arm up to 30 days after the
procedure. Other outcome measures include 12-month sur-
vival, aneurysm-related survival, incidence of rupture and con-
version, aneurysm size reduction, rates of MAEs, device-
related events, and secondary intervention rates.
The screening process includes a thorough history
and physical, an ankle/brachial index, and a preoperative
Short Form-36 quality-of-life questionnaire, as well as a
preoperative angiography or a contrast-enhanced CT
scan. Follow-up physical examination, Short Form-36
quality of life, ankle/brachial index, chest radiograph, and a
CT scan of the chest are obtained before discharge at 1, 6,
and 12 months after implantation with annual follow-up
thereafter up to 5 years. The study started enrolling patients
in March 2004 and is nearing its enrollment targets. No
results are yet available.
DISCUSSION
Endovascular technology is expected to result in more
pronounced benefits in the treatment of aneurysmal disease
in the chest than in the abdomen because of the higher
morbidity of thoracic aortic procedures. The results of the
Gore TAG trials have demonstrated not only the safety and
efficacy of the device in the treatment of DTA, but also its
unequivocal superiority as compared with open surgical
repair.6 Perioperative mortality and morbidity, particularly
with respect to SCI and cardiopulmonary complications,
have been noticeably lower than those observed in open
surgical repairs. These results warranted the FDA approval
of the Gore TAG device for the treatment of DTA.
Thoracic endografts have been commercially available
in Europe and in other parts of the world for a few years,
with nearly a dozen devices having been tested or currently
in use. These endografts have been applied to a variety of
clinical settings beyond aneurysmal disease, including aor-
tic dissections, transections, and most other pathologies of
the descending thoracic aorta. The US trials have so far
resulted in one approved device, and two more are likely to
be approved within the next year or two. As of now, the
Gore TAG device is approved solely for the treatment of
DTA. The upcoming two devices are likely to carry the
same indication, because the current trials are similar in
enrollment criteria and patient populations. The only dif-
ference has been the absence of a concurrently enrolled
open surgical control group in the VALOR trial. A wider
indication may ultimately be warranted, depending on the
results of the high-risk registry group in the VALOR trial. A
similar high-risk trial with the Gore TAG device is under
way to expand the indications of the device to be more in
line with worldwide usage.
No device-specific results are yet available. There are
few differences in the design of the devices and their ana-
tomic inclusion criteria worth noting. The TX2 device is
the only device designed with an aggressive fixation mech-
anism and the only one requiring a 3-cm neck in the trials.
The other 2 devices require 2-cm minimum landing zones.
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treatment of a neck as large as 42 mm with a 46-mm
diameter graft, whereas the other two are limited to smaller
aortic diameters (37 mm). Early experience with all three
is shaping future development. The Gore TAG device has
already been modified, and the Talent device is undergoing
modifications as of this writing. Additional modifications
and improvements are to be expected from all three and
future devices to be tested in the United States.
All devices tested to date carry a large profile, ranging
from 20F to 25F, and require a large access vessel for
introduction. Access to the thoracic aorta continues to be a
main source of complications, accounting for all three
technical failures in the Gore pivotal trial. In this study, 15%
of the patients required access proximal to the femoral
artery.6 The increased prevalence of DTA in women com-
pared with abdominal aneurysms clearly exacerbates this
problem. The vascular complication rate with the TAG
device was the only category of complications that was
more frequently observed in the endovascular group. These
high rates of access complication reflect those in the litera-
ture7 and emphasize the need to use conduits as a preven-
tative measure and not as a rescue procedure. It is interest-
ing to note that the incidence of vascular complications in
the confirmatory trial was only 6% and did not differ from
the control group. This most likely reflects the increased
awareness that iliac access represents a major source of
complications for thoracic endografting unless a conduit to
a more proximal vessel is used.
Although the incidence of spinal ischemic injury was
low and less than that reported with open repair,6-10 it does
occur with thoracic endograft repair. Although previous
aortic surgery and coverage of long segments of aorta have
been reported to portend a higher risk of paraplegia with
endovascular repair of DTA,10-12 the association could not
be documented in the TAG study.
Aneurysm sac shrinkage of 38% and an expansion rate
of 17% at 2 years with the TAG device are noteworthy.6
The rate of shrinkage is lower and that of expansion higher
than the experience with other endografts.8,13 These effects
have been described with the Excluder abdominal en-
dograft14 and probably reflect the intrinsic porosity of the
ePTFE material that was used in the TAG pivotal study.
The commercially released product, however, has a mark-
edly reduced porosity after themodification and is expected
to have a different sac response to exclusion, thus avoiding
the sac expansion noted previously.
CONCLUSION
In summary, the US trials have so far resulted in one
approved device showing that endovascular repair of descend-ing thoracic aneurysms has improved on short- andmid-term
results of traditional surgical repair. Treatment may be-
come more acceptable for higher-risk patients, and new
trials are expected to expand indications of the technol-
ogy.
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